News | Heart Valve Technology | January 31, 2020

TAVR Shows Similar Safety Outcomes as Open-Heart Surgery

Five-year study in the New England Journal of Medicine compares transcatheter aortic valve replacement to Surgery and shows no statistically significant difference in mortality or stroke

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive heart valve replacement to open-heart surgery. Photo by Cedars-Sinai. TAVR performs as well as surgery for aortic valve replacement.

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive TAVR heart valve replacement to open-heart surgery. The study showed the two methods have similar outcomes. Photo by Cedars-Sinai.

January 31, 2020 — A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic valve replacement (TAVR), had similar key five-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve. 

The study, the PARTNER 2A study, compares long-term outcomes of the two different approaches to treating aortic stenosis, a common heart problem affecting some 12% of people over 65. The research, involving more than 2,000 patients, was published today by The New England Journal of Medicine and will appear in the Feb. 27 print edition.[1]

"The results of this study are encouraging because TAVR was comparable in terms of outcomes," said study lead author Raj Makkar, M.D., vice president of Cardiovascular Innovation and Intervention at Cedars-Sinai. "These findings allow patients to have more peace of mind and undergo a less invasive procedure. Unlike surgery, TAVR is now often done without or with minimal anesthesia and with next-day discharge from the hospital."

During the TAVR procedure, an interventional cardiologist inserts a replacement valve into a catheter and guides it through an artery to the patient's heart, where a balloon is expanded to press the valve into place. 

According to the American Heart Association, nearly 1.5 million people in the U.S. have aortic valve stenosis, a narrowing or hardening of the aortic valve caused by calcium buildup on the heart valve flaps. Patients with a severe form of the disease experience symptoms including shortness of breath, chest pain, fatigue and fainting. Many cannot even walk enough to perform basic daily activities.

Aortic stenosis often results in death within three years of diagnosis. Replacing the aortic valve – either through the TAVR procedure or surgery – restores patients' life expectancy to normal. During 2019, more than 100,000 patients underwent TAVR procedures in the U.S., compared to about 50,000 patients who had aortic valve replacement with open-heart surgery.

Study investigators at 57 medical centers followed approximately 1,000 aortic stenosis patients who underwent the minimally invasive procedure and 1,000 patients who underwent open-heart surgery. The patients were followed for five years, beginning in 2011. Investigators found:

There was no statistical difference between the two groups in mortality rates or disabling stroke rates;
   • At five years follow-up, both TAVR patients and open-heart surgery patients experienced similar improvements in disease-specific quality-of-life measures;
   • The rate of aortic valve reintervention over 5 years was 3.2% for TAVR patients compared to 0.8% with surgery. Nonetheless, reintervention with TAVR was associated with lower mortality than surgery.

Patients who had TAVR performed using a transfemoral approach (from the groin to the heart) and open-heart surgery patients both had better outcomes than patients who underwent TAVR performed through an incision in the chest area.

"This landmark study clarifies the long-term pros and cons of surgical versus percutaneous interventions for the aortic valve," said Eduardo Marbán, M.D., Ph.D., executive director of the Smidt Heart Institute. "As one of the top enrolling sites, the Smidt Heart Institute is particularly proud of Dr. Makkar’s leadership of this exceptionally talented team of clinical investigators."

Makkar believes the results would be more striking with the TAVR valve now in current use by physicians because of the improvements in technology and implantation techniques. Newer valves being manufactured today come with a skirt designed to reduce leak around the valve and in more sizes, which is important for correct sizing of the valve implant.

The study was funded by Edwards Lifesciences. Makkar has received research grants and travel support for proctoring from Edwards Lifesciences.

Read more in Discoveries: Safer Heart Surgeries 

Related TAVR Content:

FDA Approves TAVR for Low-risk Patients Creates A Paradigm Shift in Cardiology

VIDEO: The Expansion of TAVR Following the FDA Clearing its Use in All Patients

VIDEO: Overview of the TAVR Program at Tufts Medical Center

Edwards Sapien 3 TAVI Granted European Approval to Treat Low-risk Patients

VIDEO: Tracking Transcatheter Valve Outcomes in the STS-ACC TVT Registry — John Carroll, M.D.

VIDEO: Transcatheter Mitral Valve Replacement Planning — Interview with Joao Cavalcante, M.D.

VIDEO: Overview of University of Colorado Structural Heart Program — Interview with John Carroll, M.D., Robert Quaife, M.D., and James Chen, Ph.D.

TAVR Operator and Hospital Requirements Outlined in 2018 AATS/ACC/SCAI/STS Expert Consensus




1. Raj R. Makkar, Vinod H. Thourani, Michael J. Mack, et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. New England Journal of Medicine. Published online Jan. 29, 2020. DOI: 10.1056/NEJMoa1910555.

Related Content

News | Cardiovascular Clinical Studies

January 26, 2023 — A newly-released study extends the understanding of how acquired mutations in blood cells act as a ...

Home January 26, 2023
News | Cardiovascular Clinical Studies

January 24, 2023 — Four cardiology organizations have joined forces in a call to action to reinvent randomized clinical ...

Home January 24, 2023
News | Cardiovascular Clinical Studies

January 11, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies ...

Home January 11, 2023
News | Cardiovascular Clinical Studies

January 3, 2023 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac ...

Home January 03, 2023
News | Cardiovascular Clinical Studies

December 30, 2022 — The Cardiovascular Research Foundation (CRF) recently announced that Alexandra Popma, MD, has joined ...

Home December 30, 2022
News | Cardiovascular Clinical Studies

December 28 2022 — Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of ...

Home December 28, 2022
News | Cardiovascular Clinical Studies

December 27, 2022 — A groundbreaking new clinical trial to determine the effectiveness of a new treatment for patients ...

Home December 27, 2022
News | Cardiovascular Clinical Studies

December 21, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting ...

Home December 21, 2022
News | Cardiovascular Clinical Studies

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

Home December 13, 2022
News | Cardiovascular Clinical Studies

December 9, 2022 — BioSig Technologies, Inc. an advanced digital signal processing technology company delivering ...

Home December 09, 2022
Subscribe Now